Clinical trial
A Randomized Double-blind Placebo-controlled Study to Evaluate the Efficacy and Safety of Cinacalcet for the Treatment of Hypercalcemia in Subjects With Primary Hyperparathyroidism Unable to Undergo Parathyroidectomy
NCT00975221 is registered in ClinicalTrials.gov with Amgen as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Randomized Double-blind Placebo-controlled Study to Evaluate the Efficacy and Safety of Cinacalcet for the Treatment of Hypercalcemia in Subjects With Primary Hyperparathyroidism Unable to Undergo Parathyroidectomy
- Lead sponsor
- Amgen
- Phase
- Phase 3
- Overall status
- Completed
- Start date
- March 10, 2010
- Completion date
- December 21, 2012
- Enrollment
- 67 (actual)
- Sites
- 47
Conditions
As the registry lists them; a condition with its own page is linked.